Academic Press Developing Costimulatory Molecules for Immunotherapy of Diseases

Product Description Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Review "...a solid framework to understand costimulation and its role in selected diseases...best serves as a fundamental review of costimulation with clinical correlates for the basic-science researcher." -- Annals of Allergy, Asthma & Immunology Review Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families About the Author Dr. Manzoor Mir completed his masters in life sciences with gold medal and after qualifying for the prestigious JRF-NET-CSIR examination, completed his Ph. D in immunopathology at JNU. His Ph. D work includes understanding the role of reverse co-stimulation in the survival of intracellular pathogens and cancer. His research areas include costimulation biology and stroke immunology. He is Assistant Professor at the Department of Bioresources at the University of Kashmir and presently works as Research Scientist at Majmaah University KSA. He has published several international research papers, review articles, and books.